Investigation of plaque vulnerability: Identification of atherosclerotic plaque angiogenesis using Bevacizumab-800CW and optoacoustic imaging: a single center proof of concept study (CAROTID-OPTOLIGHT)

Investigation of plaque vulnerability: Identification of atherosclerotic plaque angiogenesis using Bevacizumab-800CW and optoacoustic imaging: a single center proof of concept study (CAROTID-OPTOLIGHT) - Carotid Optolight

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON45786

Enrollment

Registered

2018-11-06

Start date

2019-04-29

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

atherosclerotic plaque Carotid plaque

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1) Patients with significant and symptomatic carotid stenosis who are scheduled for carotid endarterectomy as decided by the Multi-Disciplinary Carotid Board

Exclusion criteria

Exclusion criteria: 1) Medical or psychiatric condition that compromise the patient*s ability to give informed consent 2) Pregnant or lactating women 3) Significant renal (creatinine >110 µmol/L) dysfunction 4) History of iodine allergy or anaphylactic reactions to insect bites or medication or previous allergic reaction to bevacizumab 5) Presence or history of hyperthyroidism

Design outcomes

Primary

Measure	Time frame
- To investigate whether it*s feasible to detect the carotid arteries and carotid plaques using optoacoustic imaging with the MSOT Acuity Echo in patients with symptomatic carotid stenosis. - Pre-operative detection of atherosclerotic plaques in carotid stenosis with VEGF-targeted Bevacizumab-800CW using NIRF, to evaluate if upregulated VEGF within the atherosclerotic plaque can be detected non-invasively, in which duplex findings and patients history are considered the gold standard.	—

Measure

Time frame

- To investigate whether it*s feasible to detect the carotid arteries and carotid plaques using optoacoustic imaging with the MSOT Acuity Echo in patients with symptomatic carotid stenosis. - Pre-operative detection of atherosclerotic plaques in carotid stenosis with VEGF-targeted Bevacizumab-800CW using NIRF, to evaluate if upregulated VEGF within the atherosclerotic plaque can be detected non-invasively, in which duplex findings and patients history are considered the gold standard.

—

Secondary

Measure	Time frame
- Presence of fluorescent signal when endarterectomy is performed.	—

Countries

Netherlands

Outcome results